Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agile Therapeutics, a specialty pharmaceutical company focused on developing and commercialising women's healthcare products that address unmet needs, has named Al Altomari as the new president and CEO.
Subscribe to our email newsletter
Altomari, a former senior manager at Johnson & Johnson, has been serving as Agile’s executive chairman. He will succeed Thomas Rossi, who joined Agile as president and CEO in 2004. Rossi will serve as scientific advisor to the company.
Most recently, Altomari was the CEO of Barrier Therapeutics and spearheaded commercialisation of Barrier’s product portfolio and completed the sale of Barrier to GSK/Stiefel Laboratories.
Altomari said that it has been a pleasure working with Thom throughout his tenure. His leadership of Agile has set a high bar for innovating in the area of women’s health, and he will be grateful for the opportunity to take this successful and thriving organisation to the next level.
Agile has completed patient enrollment in a pivotal, Phase 3 New Choice Study of AG200-15, its lead contraceptive patch candidate, two months ahead of schedule.
This will enable Agile to plan for an earlier submission of the new drug application (NDA) for AG200-15 to the US Food and Drug Administration (FDA).